Taken together, these data suggest that the Raf/MEK/ERK pathway may represent an important therapeutic target for the treatment of HCC in patients with differing etiologies that lead to the development of this aggressive tumor. The gene discussed is MAPK1; the disease is hepatocellular carcinoma.